We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

23 hedge funds and large institutions have $4.68M invested in Immix Biopharma in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

5% more funds holding

Funds holding: 22 → 23 (+1)

4% less capital invested

Capital invested by funds: $4.9M → $4.68M (-$220K)

2.41% less ownership

Funds ownership: 10.53% → 8.11% (-2.4%)

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$85.8K
2
BlackRock
BlackRock
New York
+$57.3K
3
VCIM
Velan Capital Investment Management
Georgia
+$50.3K
4
TW
TritonPoint Wealth
Maryland
+$49.4K
5
VF
Virtu Financial
New York
+$35.9K

Top Sellers

Rank Fund Capital Flow
1
CCC
Cable Car Capital
California
-$1.31M
2
XT
XTX Topco
Cayman Islands
-$21.6K
3
FIA
FNY Investment Advisers
New York
-$18K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.93K
5
Northern Trust
Northern Trust
Illinois
-$2.77K
Name Holding Trade Value Shares
Change 		Change in
Stake
BL
1
Bleichroeder LP
New York
$1.76M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.45M – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$334K +$751 +373 +0.2%
Morgan Stanley
4
Morgan Stanley
New York
$259K +$85.8K +42,627 +52%
Northern Trust
5
Northern Trust
Illinois
$194K -$2.77K -1,374 -1%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$105K -$8.93K -4,436 -8%
State Street
7
State Street
Massachusetts
$88.9K – – –
BlackRock
8
BlackRock
New York
$83.4K +$57.3K +28,477 +241%
PAG
9
Private Advisor Group
New Jersey
$64.6K – – –
TAM
10
Tocqueville Asset Management
New York
$60.7K – – –
VCIM
11
Velan Capital Investment Management
Georgia
$51.8K +$50.3K +25,000 New
TW
12
TritonPoint Wealth
Maryland
$50.8K +$49.4K +24,526 New
VF
13
Virtu Financial
New York
$37K +$35.9K +17,846 New
SS
14
SBI Securities
Japan
$36.2K – – –
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$33K -$2.01K -1,000 -6%
UBS Group
16
UBS Group
Switzerland
$28.9K +$7.75K +3,851 +38%
Focus Partners Wealth
17
Focus Partners Wealth
Massachusetts
$24.6K – – –
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$23K +$22.5K +11,168 New
Raymond James Financial
19
Raymond James Financial
Florida
$1.09K +$1.06K +525 New
Wells Fargo
20
Wells Fargo
California
$683 – – –
Bank of America
21
Bank of America
North Carolina
$288 +$38 +19 +16%
TRCT
22
Tower Research Capital (TRC)
New York
$271 -$684 -340 -72%
Northwestern Mutual Wealth Management
23
Northwestern Mutual Wealth Management
Wisconsin
$166 – – –
CCC
24
Cable Car Capital
California
– -$1.31M -779,358 Closed
XT
25
XTX Topco
Cayman Islands
– -$21.6K -12,833 Closed
1
2

IMMX Hedge Fund Activity: Q2 2025 in Review

23 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q2 2025, worth a combined $4.68M — down 4.5% from $4.9M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IMMX positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $85.8K. The largest seller was Cable Car Capital, exiting entirely with an estimated $1.31M sold.

  • 23 institutional investors held Immix Biopharma (IMMX) as of Q2 2025, up from 22 in Q1 2025.
  • Funds reported $4.68M of Immix Biopharma stock for Q2 2025, down 4.5% quarter-over-quarter.
  • 5 funds opened new Immix Biopharma positions in Q2 2025 and 4 closed out, a net change of +1 holder.
  • The largest Immix Biopharma buyer in Q2 2025 was Morgan Stanley, an estimated $85.8K added.
  • The largest Immix Biopharma seller in Q2 2025 was Cable Car Capital, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2025.